Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) and keeping the price target at $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Capricor Therapeutics’ progress with their lead cell therapy, Deramiocel, for Duchenne Muscular Dystrophy (DMD). The recent completion of the FDA’s pre-license inspection of their San Diego facility, despite minor observations, indicates a positive regulatory trajectory, with no anticipated impact on their manufacturing process. The upcoming FDA Advisory Committee meeting and the priority review of their Biologics License Application (BLA) further bolster confidence in the potential approval of Deramiocel.
Additionally, the strategic partnership with Nippon Shinyaku for commercialization in the US, Japan, and the EU, along with significant milestone payments and revenue sharing, positions Capricor favorably in the market. The absence of approved therapies for DMD-cardiomyopathy and the demonstrated efficacy of Deramiocel in improving cardiac function suggest a strong market opportunity. The company’s preparations for commercial launch, including facility expansion to increase patient capacity, further support the Buy rating as they are well-positioned to meet anticipated demand upon approval.
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Gain Therapeutics, and Actinium Pharmaceuticals. According to TipRanks, McCarthy has an average return of -19.4% and a 29.03% success rate on recommended stocks.
In another report released today, Roth MKM also reiterated a Buy rating on the stock with a $31.00 price target.